-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewHuman Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat....
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewAngioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024
Empower your strategies with our Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024 report and make more profitable business decisions. Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections....
-
Product Insights
NewLeiomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
NewLymphocryptovirus Infections – Drugs In Development, 2024
Empower your strategies with our Lymphocryptovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Lymphocryptovirus infections are caused by a genus of herpesviruses that infect humans and other primates. The most well-known lymphocryptovirus is the Epstein-Barr virus (EBV), which can cause mononucleosis, lymphoma, and nasopharyngeal carcinoma in humans. Lymphocryptovirus infections are usually latent, meaning that the virus remains dormant in the host cells until it is reactivated by stress or immune suppression. Lymphocryptovirus infections can be...
-
Product Insights
NewPeripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024
Empower your strategies with our Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral T-cell lymphomas (PTCL) constitute a diverse group of rare and aggressive non-Hodgkin lymphomas originating from mature T cells. These malignancies involve lymphoid tissues and may affect organs throughout the body. PTCLs are heterogeneous, comprising various subtypes with distinct clinical behaviors and outcomes. Symptoms may include enlarged lymph nodes, fever, weight loss, and night sweats. Diagnosis involves biopsies, imaging studies,...
-
Product Insights
NewNasopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Nasopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose, an area called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking including hoarseness, recurrent ear infections, face pain or numbness, headache, hearing loss, and...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...